Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 12/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25421846 | 1.00 | BRD4 (0.46) | BRD4MAPK8PTGS2MAPK14MAPK11 | |
| SCHEMBL26077874 | 0.84 | MAPK8 (0.33) | BRD4MAPK8PTGS2MAPK14MAPK11 | |
| SCHEMBL29537104 | 0.83 | MET (0.35) | BRD4MAPK8PTGS2MAPK14 | |
| SCHEMBL25420591 | 0.83 | MET (0.35) | BRD4MAPK8PTGS2MAPK14 | |
| SCHEMBL29536937 | 0.79 | L3MBTL1 (0.33) | PTGS2MAPK14 | |
| SCHEMBL30595902 | 0.77 | MAPK8 (0.41) | MAPK8MAPK14 | |
| SCHEMBL26075404 | 0.77 | MAPK8 (0.41) | MAPK8MAPK14 | |
| SCHEMBL29537219 | 0.77 | MAPK14 (0.32) | BRD4MAPK8MAPK14 | |
| SCHEMBL30595879 | 0.75 | SYK (0.44) | MAPK8 | |
| SCHEMBL26075403 | 0.75 | SYK (0.44) | MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | BRD4 924/4885MAPK8 124/4885PTGS2 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.